How a 'regulatory dead zone' may be holding up copycat insulin

How a 'regulatory dead zone' may be holding up copycat insulin

Source: 
Biopharma Dive
snippet: 

The insulin market has increasingly attracted scrutiny from politicians, regulators and patient groups, as prices ramp higher for the hormone that millions of diabetics depend on to stay alive.